Atopic Dermatitis
Shorts
Podcasts
Continuing Medical Education
All News
Advertisement
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Rezpegaldesleukin improved EASI, itch, and other outcomes in phase 2b REZOLVE-AD, supporting continued phase 3 development.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
MotherToBaby launched a pregnancy study to address limited safety data for lebrikizumab use in patients with atopic dermatitis.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Elevate-Derm expert panel offers practical JAK inhibitor pearls on cholesterol, comorbid autoimmune disease, and shared decision-making.
In this episode, Renata Block, DMSCc, MMS, PA-C, discusses the new ICD-10 code for topical steroid withdrawal with Kelly Barta, the president and executive director of the International Topical Steroid Awareness Network.
Survey highlights APP autonomy, prescribing confidence, and treatment priorities in atopic dermatitis care
Advertisement
Hormonal shifts shape psoriasis and atopic dermatitis through puberty, pregnancy, postpartum, and menopause, guiding safer treatment choices and protecting pregnancy outcomes.
The FDA accepted an sNDA for roflumilast cream 0.05% in infants, potentially expanding steroid-free treatment options for atopic dermatitis.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Derm-Biome Pharmaceuticals reported positive preclinical results for DB-006, a small molecule reducing itch, inflammation, and IgE levels in a model of atopic dermatitis.
Turn Therapeutics is preparing to request an FDA meeting to discuss regulatory strategy and potential pathways toward market following successful Phase 2 completion.
Apogee plans to initiate 3 phase 3 trials of zumilokibart in moderate to severe atopic dermatitis—ADventure 1, ADventure 2, and ADventure TCS—in the second half of 2026.
Among more than 1700 patients enrolled in the long-term extension study, the majority transitioned from a moderate to severe AD phenotype at baseline to a mild phenotype within 12 weeks, with that shift maintained through 2 years.
Clinical outcomes improved in both switch directions following treatment modification, with substantial reductions in PASI and EASI scores.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
In this episode, Renata Block, DMSc, MMS, PA-C, and Zachary Rubin, MD, discuss the overlapping worlds of allergy and dermatology—and how better cross-specialty understanding can dramatically improve patient outcomes.
Early clinical trials indicate that dual- and triple-target antibodies may provide faster onset and more consistent itch relief in moderate to severe AD.
Affecting up to 25% of children worldwide, pediatric AD carries a significant quality of life burden that extends to caregivers.
In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.
Eight in ten ADlong patients achieved clinical response without steroid rescue, strengthening the case for lebrikizumab as a standalone, long-term management option.
Missed the late-breaking sessions? Review our quick guide of all the need-to-know data from AAD 2026.
Phase 2 APEX part A data showed zumilokibart maintained EASI-75 responses in 75–85% of week 16 responders at 1 year across quarterly and biannual dosing regimens.
Renata Block, DMSc, MMS, PA-C, and Jamie Restivo, MPAS, PA-C, explore how hypochlorous acid sprays and sodium hypochlorite washes simplify AD adjunct care, improving adherence, antimicrobial control, and symptom relief.
Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed clinical cases highlighting the distinct roles of topical ruxolitinib, tapinarof, and roflumilast in managing itch, inflammation, and long-term disease control in atopic dermatitis.
Omar Noor, MD, shares pearls on type 2 inflammation, including dupilumab insights for atopic dermatitis, prurigo nodularis, and CSU at Horizons in Advanced Practice.
A combined group of ophthalmology and dermatology specialists traveled to communities in Nepal to conduct consultations, procedures, and teaching sessions, and specifically in dermatology, skin malignancy removals, trainings on biologics and JAKs, and melanoma detection demonstrations.
Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.
Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed the 3 latest non-steroidal topicals for atopic dermatitis at the Horizons in Advanced Practice meeting.
Advertisement
Advertisement
Trending on Dermatology Times
1
Galderma to Acquire ZO Skin Health for $1.5 Billion
2
Exosome Progress and Remibrutinib Label Expansion
3
Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS
4
Chronic Hand Eczema Linked to Lost Productivity and Lower Quality of Life
5